Floatz logo

Campath-1H

Solid Tumors

David Rizzieri, MDmonoclonal_antibodyPhase 2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
65/ 100

Competitive context

208 Active assets in the Solid Tumors cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
Hellenic Society of Hematology
Phase 3BB
FILGRASTIM
Ankara Etlik City Hospital
Phase 2BB
Carboplatin
Bristol-Myers Squibb
Phase 3BB
Ribociclib
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 4B
Irinotecan
Mirati Therapeutics Inc.
Phase 3B

View all 50 →

Same molecule, other indications

Campath-1H is also rated in:

MyelodysplasiaDormant
CCC
Indicative ·
55 / 100
View asset →
MyelomaDormant
CCC
Indicative ·
52 / 100
View asset →
myelodysplastic syndromeDormant
CCC
Indicative ·
49 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →